X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12866) 12866
Book Chapter (125) 125
Book / eBook (18) 18
Publication (10) 10
Dissertation (9) 9
Web Resource (9) 9
Newsletter (8) 8
Magazine Article (4) 4
Conference Proceeding (3) 3
Book Review (2) 2
Newspaper Article (1) 1
Paper (1) 1
Reference (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6939) 6939
animals (5960) 5960
pharmacology & pharmacy (5818) 5818
prodrugs - pharmacology (3658) 3658
prodrugs (3155) 3155
male (2927) 2927
chemistry, medicinal (2659) 2659
prodrug (2562) 2562
prodrugs - chemistry (2467) 2467
mice (2452) 2452
rats (2061) 2061
prodrugs - pharmacokinetics (2029) 2029
female (1983) 1983
prodrugs - chemical synthesis (1699) 1699
prodrugs - metabolism (1506) 1506
cell line, tumor (1481) 1481
cancer (1477) 1477
antineoplastic agents - pharmacology (1377) 1377
prodrugs - administration & dosage (1347) 1347
chemistry, multidisciplinary (1345) 1345
biochemistry & molecular biology (1332) 1332
pharmacokinetics (1319) 1319
structure-activity relationship (1221) 1221
prodrugs - therapeutic use (1158) 1158
drug delivery systems (1107) 1107
in-vitro (1089) 1089
hydrolysis (1087) 1087
drugs (1055) 1055
molecular structure (998) 998
oncology (960) 960
dose-response relationship, drug (903) 903
administration, oral (900) 900
antineoplastic agents - chemistry (887) 887
solubility (862) 862
drug design (832) 832
analysis (812) 812
chemistry, organic (790) 790
derivatives (749) 749
adult (722) 722
rats, sprague-dawley (715) 715
cell survival - drug effects (714) 714
metabolism (692) 692
drug stability (672) 672
delivery (667) 667
chemotherapy (648) 648
kinetics (643) 643
chromatography, high pressure liquid (624) 624
cells (619) 619
nanoparticles (613) 613
drug-delivery (608) 608
neoplasms - drug therapy (595) 595
therapy (594) 594
cell line (592) 592
biological availability (587) 587
middle aged (578) 578
pharmacology (577) 577
hydrogen-ion concentration (564) 564
design (562) 562
antineoplastic agents - chemical synthesis (552) 552
enzymes (536) 536
antiviral agents - pharmacology (524) 524
cytotoxicity (520) 520
in-vivo (514) 514
tumor cells, cultured (514) 514
cell proliferation - drug effects (508) 508
drug screening assays, antitumor (501) 501
pharmacology/toxicology (499) 499
expression (496) 496
in vitro techniques (491) 491
drug delivery (480) 480
medicine, research & experimental (471) 471
esters (468) 468
mice, nude (468) 468
tumors (466) 466
activation (465) 465
permeability (462) 462
toxicity (446) 446
biotransformation (443) 443
apoptosis (440) 440
research (437) 437
chemistry (433) 433
half-life (432) 432
microbiology (424) 424
mice, inbred balb c (422) 422
rats, wistar (422) 422
bioavailability (402) 402
doxorubicin (402) 402
care and treatment (396) 396
magnetic resonance spectroscopy (388) 388
tissue distribution (387) 387
time factors (379) 379
absorption (377) 377
aged (376) 376
health aspects (376) 376
antineoplastic agents - therapeutic use (375) 375
xenograft model antitumor assays (373) 373
dogs (370) 370
inhibition (370) 370
pharmacy (367) 367
enzyme inhibitors - pharmacology (365) 365
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12854) 12854
Japanese (319) 319
Chinese (40) 40
German (34) 34
French (27) 27
Russian (11) 11
Portuguese (9) 9
Spanish (9) 9
Slovak (5) 5
Czech (4) 4
Dutch (2) 2
Italian (2) 2
Korean (2) 2
Croatian (1) 1
Finnish (1) 1
Hungarian (1) 1
Norwegian (1) 1
Polish (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Antimicrobial agents and chemotherapy, ISSN 1098-6596, 2018, Volume 62, Issue 3, p. e02319-17
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2017, Volume 12, Issue 7, p. e0179431
Cytokines are potent immune modulating agents but are not ideal medicines in their natural form due to their short half-life and pleiotropic systemic effects.... 
LIGAND-BINDING | ALPHA-RECEPTOR | MULTIDISCIPLINARY SCIENCES | LONG-TERM SAFETY | COMPLEXES | REGULATORY T-CELLS | MODULATION THERAPIES | IL-2 | CYTOKINE | HIGH-DOSE INTERLEUKIN-2 | RENAL-CELL CARCINOMA | Neoplasms - metabolism | T-Lymphocytes, Regulatory - metabolism | Immunotherapy - methods | Interleukin-2 Receptor beta Subunit - metabolism | Interleukin Receptor Common gamma Subunit - metabolism | Transplantation, Homologous | T-Lymphocytes, Regulatory - immunology | STAT5 Transcription Factor - metabolism | Neoplasms - therapy | Interleukin Receptor Common gamma Subunit - agonists | CD8-Positive T-Lymphocytes - metabolism | Female | Interleukin-2 - analogs & derivatives | Phosphorylation - drug effects | Polyethylene Glycols - pharmacology | Models, Theoretical | Tumor Microenvironment - drug effects | Interleukin-2 - pharmacokinetics | Interleukin-2 Receptor beta Subunit - agonists | Mice, Inbred C57BL | Polyethylene Glycols - pharmacokinetics | Receptors, Interleukin-2 - metabolism | Mice, Inbred C3H | Tumor Microenvironment - immunology | T-Lymphocytes, Regulatory - drug effects | Algorithms | Animals | Interleukin-2 Receptor alpha Subunit - agonists | Interleukin-2 Receptor alpha Subunit - metabolism | Prodrugs - pharmacokinetics | Neoplasms - immunology | CD8-Positive T-Lymphocytes - drug effects | Cell Line, Tumor | Drug Liberation | Interleukin-2 - pharmacology | Mice, Inbred BALB C | Kinetics | CD8-Positive T-Lymphocytes - immunology | Prodrugs - pharmacology | Receptors, Interleukin-2 - agonists | Physiological aspects | Care and treatment | Interleukin-2 | Immunotherapy | Patient outcomes | Cancer | Polyethylenes | Conjugates | CD8 antigen | Interleukin | Lymphocytes T | Anticancer properties | Proteins | Biological effects | Cell activation | Immunology | Interleukin 2 | Lymphocytes | Polyethylene glycol | Modelling | Drug dosages | Immune system | Interleukin 2 receptors | Pharmacodynamics | Cytokines | Immunoregulation | Melanoma | Pharmacology | Affinity | Ligands | Mutation | Pharmacokinetics | In vitro methods and tests | Tumors
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects
Journal Article
Current Pharmaceutical Design, ISSN 1381-6128, 04/2008, Volume 14, Issue 10, pp. 1001 - 1047
Amidoximes are compounds bearing both a hydroxyimino and an amino group at the same carbon atom which makes them versatile building blocks for the synthesis of... 
Amidines | Biological activities | Prodrugs | Amidoximes | NO donors | amidines | DIRECT THROMBIN INHIBITOR | SOLID-PHASE SYNTHESIS | NITRIC-OXIDE SYNTHASE | HUMAN LIVER-MICROSOMES | prodrugs | CYTOCHROME B REDUCTASE | METABOLIC N-HYDROXYLATION | biological activities | amidoximes | FIBRINOGEN RECEPTOR ANTAGONISTS | PHARMACOLOGY & PHARMACY | PNEUMOCYSTIS-CARINII PNEUMONIA | HYDROXY-L-ARGININE | FACTOR XA INHIBITOR | Antihypertensive Agents - pharmacology | Nitric Oxide Donors - chemistry | Antioxidants - chemistry | Anti-Arrhythmia Agents - pharmacology | Anti-Infective Agents - pharmacology | Antineoplastic Agents - chemical synthesis | Humans | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Prodrugs - chemistry | Anti-Allergic Agents - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Platelet Aggregation Inhibitors - chemical synthesis | Anti-Allergic Agents - chemical synthesis | Anti-Infective Agents - chemistry | Anti-Allergic Agents - chemistry | Platelet Aggregation Inhibitors - pharmacology | Antineoplastic Agents - pharmacology | Nitric Oxide Donors - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis | Central Nervous System Agents - chemistry | Pesticides - chemical synthesis | Anti-Arrhythmia Agents - chemistry | Antihypertensive Agents - chemical synthesis | Antioxidants - chemical synthesis | Antioxidants - pharmacology | Oximes - chemical synthesis | Antineoplastic Agents - chemistry | Anti-Infective Agents - chemical synthesis | Oximes - chemistry | Antihypertensive Agents - chemistry | Anti-Arrhythmia Agents - chemical synthesis | Central Nervous System Agents - pharmacology | Platelet Aggregation Inhibitors - chemistry | Oximes - pharmacology | Pesticides - chemistry | Prodrugs - chemical synthesis | Nitric Oxide Donors - chemical synthesis | Central Nervous System Agents - chemical synthesis | Prodrugs - pharmacology | Pesticides - pharmacology
Journal Article
Book Review
Molecular Cancer Therapeutics, ISSN 1535-7163, 03/2012, Volume 11, Issue 3, pp. 740 - 751
Journal Article
癌症:英文版, ISSN 1000-467X, 2014, Volume 33, Issue 2, pp. 80 - 86
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 01/2016, Volume 60, Issue 1, pp. 316 - 322
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 2003, Volume 111, Issue 11, pp. 1665 - 1672
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 09/2013, Volume 57, Issue 9, pp. 4172 - 4180
Journal Article
Seminars in Thrombosis and Hemostasis, ISSN 0094-6176, 2005, Volume 31, Issue 2, pp. 184 - 194
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 05/2012, Volume 134, Issue 18, pp. 7978 - 7982
Journal Article
The FEBS Journal, ISSN 1742-464X, 12/2015, Volume 282, Issue 24, pp. 4747 - 4765
Renal cell carcinoma (RCC) is resistant to traditional cancer therapies, and metastatic RCC (mRCC) is incurable. The shortcomings in current therapeutic... 
apoptosis | triptolide | renal cell carcinoma | TRAIL | death receptor | HEAT-SHOCK-PROTEIN-70 INHIBITS APOPTOSIS | DENDRITIC CELLS | (TRAIL)-INDUCED APOPTOSIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANTI-DR5 ANTIBODY THERAPY | HEAT-SHOCK PROTEINS | TUMOR-NECROSIS-FACTOR | APOPTOSIS-INDUCING LIGAND | IN-VIVO | NF-KAPPA-B | PANCREATIC-CANCER CELLS | Recombinant Proteins - therapeutic use | Neoplasm Transplantation | Antineoplastic Combined Chemotherapy Protocols - chemistry | Apoptosis - drug effects | Receptors, TNF-Related Apoptosis-Inducing Ligand - agonists | Humans | Organophosphates - therapeutic use | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Receptors, TNF-Related Apoptosis-Inducing Ligand - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Epoxy Compounds - pharmacology | TNF-Related Apoptosis-Inducing Ligand - pharmacology | TNF-Related Apoptosis-Inducing Ligand - agonists | Female | Antineoplastic Agents - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Carcinoma, Renal Cell - drug therapy | Antibodies, Monoclonal - chemistry | Diterpenes - pharmacology | Epoxy Compounds - therapeutic use | Diterpenes - therapeutic use | Phenanthrenes - therapeutic use | Specific Pathogen-Free Organisms | Carcinoma, Renal Cell - pathology | Antibodies, Monoclonal - pharmacology | Recombinant Proteins - chemistry | Recombinant Proteins - pharmacology | Antineoplastic Agents - chemistry | TNF-Related Apoptosis-Inducing Ligand - therapeutic use | Drug Synergism | Organophosphates - pharmacology | Carcinoma, Renal Cell - metabolism | Phenanthrenes - pharmacology | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Cell Line, Tumor | Kidney Neoplasms - pathology | Mice | Mice, Inbred BALB C | Prodrugs - therapeutic use | Antineoplastic Agents, Phytogenic - pharmacology | Kidney Neoplasms - drug therapy | Prodrugs - pharmacology | TNF-Related Apoptosis-Inducing Ligand - genetics | Heat shock proteins | Carcinoma, Renal cell | Rodents | Tumors | Apoptosis
Journal Article